Prolonged weakness in hospitals’ capital spending and limited orthopaedic implant volumes continue to impact negatively on Stryker’s earnings. The Kalamazoo, Michigan-based company recorded Q3 sales of $1.65bn, which were flat compared with the same period in 2008. Stryker incurred ...
Please Login to read the full article.
